CB
LONGINSIDER SELLCONGRESS BUYCHUBB LTD SWITZ
Research: Finviz ↗·Perplexity ↗
🗄 Viewing archived Q1 2026 data — frozen, no longer refreshed.
News Summary
NeutralChubb delivered strong H1 2026 financial performance with 14.6% YoY earnings growth in Q2, beat expectations, and raised guidance to $27–$28.50 EPS for full year 2026 with double-digit growth targets intact. However, significant headwinds are emerging: property market pricing has collapsed 25–40% in key markets, soft conditions are spreading to casualty lines, and the company is intentionally shrinking its large-account and E&S property business due to adverse pricing environment.
Red flags
- •Property market pricing declined 25–40% in North America, London, and larger premiums, described by management as 'dumb' pricing
- •Soft market conditions spreading beyond property to casualty lines with pricing failing to keep pace with loss costs
- •Corporate runoff portfolio experienced $158 million adverse development from molestation-related claims
- •Intentional shrinkage of large-account and E&S property business due to market conditions, signaling strategic retreat from certain segments
Funds Buying (3)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | % of Fund | QoQ | Status |
|---|---|---|---|---|---|---|---|
| Viking Global | Andreas Halvorsen | 1.3M | +281K | $422M | 1.2% | +28% | Existing |
| Point72 | Steve Cohen | 32K | +32K | $11M | <0.1% | — | NEW |
| Soros Fund Management | Soros Family Office | 23K | +23K | $7M | 0.1% | — | NEW |
Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter. % of Fund is the position's share of the fund's reported equity portfolio — it drives the size weighting in the conviction score.
Portfolio Context
Where CB ranks in each buying fund's book, and the positions immediately around it. What a holding sits next to often says more about the thesis than the position size does.
position #34 of this fund's book
- 31ATI INC$485M
- 32CELESTICA INC$466M
- 33CAMDEN PPTY TR$461M
- 34CHUBB LTD SWITZ$422M
- 35ADAPTIVE BIOTECHNOLOGIES COR$416M
- 36BIOMARIN PHARMACEUTICAL INC$399M
- 37SEA LTD$392M
Values are quarter-end position sizes. Shown only for funds where CB ranks inside their 40 largest equity positions — below that, neighbouring names carry no signal. Adjacency is an inference about a fund's reasoning, not a disclosure of it.
Insider Activity
| Name | Title | Type | Shares | Price | Value | Filed | Src |
|---|---|---|---|---|---|---|---|
| Wayland Joseph F | Executive Vice President and* | SELL | 9K | $364.54 | $3.10M | 2026-07-28 | ↗ |
| Ortega Juan Luis | Executive Vice President* | SELL | 4K | $322.08 | $1.25M | 2026-06-08 | ↗ |
| Keogh John W | President &COO | SELL | 20K | $321.45 | $6.49M | 2026-05-27 | ↗ |
| Keogh John W | President &COO | SELL | 3K | $321.95 | $0.91M | 2026-05-27 | ↗ |
| ATIEH MICHAEL G | — | SELL | 578 | $329.53 | $0.19M | 2026-05-21 | ↗ |
Congressional Trading
| Member | Chamber | State | Type | Amount Range | Transaction Date | Filed | Src |
|---|---|---|---|---|---|---|---|
| Alan Armstrong | senate | — | BUY | $1,001 - $15,000 | 2026-03-27 | 2026-07-21 | ↗ |
Periodic Transaction Reports filed under the STOCK Act. Amounts are disclosed as ranges, not exact dollar figures.